Search

Methaqualone

The sedative-hypnotic activity was first noted by Indian researchers in the 1950s and in 1962 methaqualone itself was patented in the US by Wallace and Tiernan. … Clandestinely produced methaqualone is still seized by government agencies and police forces around the world.

Ketoconazole

[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. … [FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.

Eperisone

It is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.

Human papillomavirus type 31 L1 capsid protein antigen

It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 31. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 31 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae

Lomefloxacin

Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.

Proparacaine

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Alunacedase alfa

Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.

Dihydroquinidine barbiturate

CMLVAX100

It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial. … CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia.

Tanaproget

Tanaproget (NSP-989) is an investigational non-steroidal progestin. … Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals.